Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Improved HCV vaccines and methods for using the same

A technology of immunogenic fragments and proteins, applied in vaccines, chemical instruments and methods, biochemical equipment and methods, etc., can solve the problem of platform immunogenicity reduction and other issues

Active Publication Date: 2014-06-25
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
View PDF56 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a major obstacle to clinical adoption of DNA vaccines is the reduction of platform immunogenicity when moving to larger animals [Liu, M.A. and J.B. Ulmer, Human clinical trials of plasma DNA vaccines. Adv Genet, 2005.55: pp. 25-40 Page]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved HCV vaccines and methods for using the same
  • Improved HCV vaccines and methods for using the same
  • Improved HCV vaccines and methods for using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Design and expression of pConNS4B, pConNS5A and pConNS5B

[0088] The HCV genotype la consensus sequence for HCV proteins NS4B, NS5A and NS5B was generated from 170 different sequences obtained from the Los Alamos National Laboratory HCV sequence database. Several modifications were then made to the consensus constructs in order to enhance their expression and detection, including the addition of the leader sequence IgE at the C-terminal and N-terminal HA-tags of each construct. Alternatively, use GeneOptimizer with codon and RNA optimization TM Each construct was further modified (GENEART, Germany) and subcloned into the clinical expression vector pVAX under the control of the CMV promoter. The final constructs were called pConNS4B, pConNS5A and pConNS5B (plasmid maps are shown in Figure 8A-Figure 8C ).

[0089] Protein expression of each construct was determined by transiently transfecting human RD myocytes with each individual construct. Using Lipofectamine TM ...

Embodiment 2

[0092] Immunization of C57BL / 6 mice with pConNS4B, pConNS5A and pConNS5B induces strong cellular immune responses

[0093] Once the expression of the construct was determined, C57BL / 6 mice were immunized to determine the immunogenicity of the construct. 6- to 8-week-old female C57BL / 6 mice were purchased from the Jackson Laboratory and maintained according to the guidelines of the National Institutes of Health and the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania. For each individual construct the animals were divided into three different feeding groups of five animals each. Animals were immunized intramuscularly with 5 μg, 12.5 μg or 25 μg of pConNS4B, pConNS5A or pConNS5B followed by electroporation.

[0094] Using CELLECTRA TM Electroporation was performed with an adaptive constant current electroporation device and electrode array (Inovio Pharmaceuticals, Inc., Blue Bell, PA).

[0095] Animals received a total of two immunizations...

Embodiment 3

[0101] Immune-induced NS4B-, NS5A-, and NS5B-specific T cells were detected in the liver after intramuscular immunization

[0102] Mice were immunized as previously described in Example 1 above. One week after the last immunization, animals were sacrificed. After sacrifice, the livers were separated and comminuted individually using a Stomacher machine. The resulting mixture was filtered and treated with 10 ml ACK lysis buffer (Bioscience) for 5 minutes to remove RBCs. The mixture was pelleted and hepatocytes were separated from lymphocytes by using a 35% Percoll gradient. The pelleted lymphocytes were resuspended in complete medium. Experiments were performed with or without hepatic perfusion and no differences were observed.

[0103] T cells were isolated from each liver and stimulated with overlapping peptides corresponding to each individual construct. Immunization-induced HCV-specific T cells were identified by IFN-γ expression detected by intracellular cytokine stai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Description

field of invention [0001] The present invention relates to improved HCV antigens and vaccines made therefrom, as well as improved methods for inducing an immune response against HCV and for prophylactically and / or therapeutically immunizing individuals. Background of the invention [0002] Applicants published co-pending US Patent Application No. 13 / 127,008 filed April 29, 2011, the disclosure of each of which is incorporated herein by reference. [0003] Hepatitis C (HCV) is a small enveloped positive-sense RNA virus that represents a major health problem worldwide, with more than 170 million individuals currently infected with the virus [Thomson, B.J. and R.G. Finch, Hepatitis C virus infection. Clin Microbiol Infect, 2005.11(2): pages 86-94]. One of the most successful of all human viruses, HCV potentially infects hepatocytes and is able to persist in the liver of up to 70% of all infected individuals [Bowen, D.G. and C.M. Walker, Adaptive immune responses in acute and c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00C07H21/04
CPCA61K48/00A61K39/12C07K14/005C12N2770/24234C12N2770/24222C07K14/05A61K2039/53A61P1/06A61P1/16A61P31/12A61P31/14A61P37/04A61K39/29C07K14/02
Inventor 大卫·韦纳克里斯特尔·朗严健鲁克桑德拉·德拉吉阿克利阿米尔·卡恩
Owner THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com